Skip to main content
Erschienen in: BMC Cardiovascular Disorders 1/2017

Open Access 01.12.2017 | Debate

Surface ECG interatrial block-guided treatment for stroke prevention: rationale for an attractive hypothesis

verfasst von: Antoni Bayés de Luna, Manuel Martínez-Sellés, Antoni Bayés-Genís, Roberto Elosua, Adrian Baranchuk

Erschienen in: BMC Cardiovascular Disorders | Ausgabe 1/2017

Abstract

Atrial fibrillation (AF) is the most common sustained arrhythmia and is associated with stroke, cognitive impairment, and cardiovascular death. Some predisposing factors − as aging, diabetes, hypertension − induce and maintain electrophysiological and ultrastructural remodeling that usually includes fibrosis. Interatrial conduction disturbances play a crucial role in the initiation of atrial fibrosis and in its associated complications. The diagnosis of interatrial blocks (IABs) is easy to perform using the surface ECG. IAB is classified as partial when the P wave duration is ≥120 ms, and advanced if the P wave also presents a biphasic pattern in II, III and aVF. IAB is very frequent in the elderly and, particularly in the case of the advanced type, is associated with AF, AF recurrences, stroke, and dementia. The anticoagulation in elderly patients at high risk of AF without documented arrhythmias is an open issue but recent data suggest that it might have a role, particularly in elderly patients with structural heart disease, high CHA2DS2VASc (Congestive heart failure/left ventricular dysfunction, Hypertension, Age ≥ 75 [doubled], Diabetes, Stroke [doubled] – Vascular disease, Age 65–74, and Sex category [female]), and advanced IAB. In this debate, we discuss the association of surface ECG IAB, a marker of atrial fibrosis, with AF and stroke. We also present the rationale that justifies further studies regarding anticoagulation in some of these patients.
Abkürzungen
- CHA2DS2VASc
Congestive heart failure/left ventricular dysfunction, Hypertension, Age ≥ 75 [doubled], Diabetes, Stroke [doubled] – Vascular disease, Age 65–74, and Sex category [female]
AF
Atrial fibrillation
CMR
Cardiac magnetic resonance
HAS-BLED
Hypertension, Abnormal renal and liver function, Stroke, Bleeding, Labile INRs, Elderly (≥65 years), Drugs or alcohol
IAB
Interatrial block

Background

Atrial fibrillation (AF) is the most common sustained arrhythmia, and is currently considered a worldwide epidemic. AF usually occurs in patients with “atria at risk”, atria that have specific characteristics, including slow conduction. Fibrosis plays a key role in this process, especially in patients that present with AF in the context of advanced heart disease and aging [1]. Fibrosis usually is the consequence of a chain of events that are triggered by abnormal activation of the left atrium due to interatrial blocks (IABs) [2]. As recognized recently, AF is not necessary the main cause of stroke but rather is another important risk factor for stroke [3]. Interatrial conduction disturbances play crucial roles in the initiation of atrial fibrosis development and its associated complications.

Interatrial block is an independent factor associated with atrial fibrillation, stroke, and cognitive impairment

IAB is the most common and well-known block at the atrial level. IABs are classified as partial IABs (P-IABs) that are observed on the surface ECG as a positive P wave ≥120 ms, or as advanced IABs (A-IABs) manifested as a P wave ≥120 ms plus biphasic (±) morphology in leads II, III, and aVF (Fig. 1). In 2012, a consensus document was published that confirmed these criteria and stated that IAB was a separate entity from left atrial enlargement [4]. IAB is frequently found in the elderly, with a prevalence of 8% in septuagenarians and 25% in centenarians [5]. The prevalence is also high in patients with structural heart disease.
The biopsy tissue of patients with lone AF show abnormal atrial histology, as do the tissues of patients with paroxysmal AF [6]. Patients with lone AF present with different degrees of interatrial conduction disturbances and, compared with controls, present with more delayed and slower intra-atrial conduction and shorter effective refractory periods [7]. Patients with A-IABs have a higher incidence of AF than those with P-IABs [8], an association that is termed Bayes’ syndrome [9]. This association of IAB and AF has been confirmed in many studies performed in different settings, mainly by groups led by Spodick and Baranchuk [10, 11]. In a large cohort of unselected individuals, the incidence of AF was higher in the presence of A-IAB [12].
The association of IABs and embolic stroke has been demonstrated in hospitalized patients [13], in the general population [14], and in patients with high CHA2DS2-VASc scores [15]. Furthermore, Martinez-Sellés et al. [5] found that in centenarians, the presence of A-IAB is associated with previous stroke and cognitive impairment.

How to measure atrial fibrosis?

Atrium fibrosis is a common feature in patients with AF, the causality of this association is not yet clarified but the association seems to be bidirectional: fibrosis increases the risk of AF that in turn induces fibrosis. In post-mortem samples, the extent of fibrosis and fatty tissue in the zones of the crista terminalis, Bachmann’s bundle region, and superior pulmonary veins is more extensive in patients with longer P-waves (P > 160 ms) [4]. Contrast-enhanced cardiac magnetic resonance (CMR) imaging may be the optimal non-invasive method for evaluating and quantifying left atrium fibrosis [16]. The amount of atrial fibrosis and the atrial strain rate, as detected by new echocardiographic techniques, correlates well with the likelihood of AF recurrence [16]. CMR imaging shows a higher mean value of fibrosis in patients with persistent vs. paroxysmal AF, yet the extent of fibrosis is not always related to the phenotype of AF. Large areas of fibrosis have been detected in some paroxysmal AF cases, while only mild fibrosis has been found in some persistent AF cases. Thus, the causal relation between AF duration and the extent of fibrosis requires further insight [16]. In patients with lone AF, the atrial substrate may progress despite successful AF ablation, indicating an independent progressive course in some cases of idiopathic atrial fibrotic cardiomyopathy.
It would be desirable to perform CMR or to use new echocardiographic techniques to determine the burden of atrial fibrosis to the full spectrum of patients at risk. In their absence, we recommend a careful analysis of the P-wave on surface ECG, which emerges as a cheap, easy and valuable surrogate of the atrial fibrotic process. Indeed, patients with A-IAB present with low atrial mobility due to the large amount of fibrosis and with reduced strain by speckle-tracking echocardiography [17]. This is important as left atrial deformation measured with speckle tracking echocardiography has been associated with AF recurrence [18]. Moreover, extensive atrial fibrosis assessed by late gadolinium enhancement CMR has been associated with advanced IAB [19].

Should anticoagulation be used in some patients with advanced interatrial block before they have documented atrial fibrillation?

A-IAB is an independent risk factor for AF and embolic stroke, and there is evidence that this risk increases in the presence of a high CHA2DS2-VASc score and advanced age. Surface ECG IAB should be considered in the risk stratification of patients in sinus rhythm that are at high risk of stroke, even if they have no documented AF [20, 21]. Also, the bleeding risk of elderly patients that receive anticoagulation should be taken into account. HAS-BLED score for major bleeding is very useful for this risk assessment, although, in the case of AF the net clinical benefit of anticoagulation seems to exist in almost all patients, as the risk of ischemic stroke without anticoagulant treatment is higher than the risk of intracranial bleeding with anticoagulant treatment [22]. However, before anticoagulation therapy is indicated in patients with no documented AF, two steps should be taken. The first step is to perform a prospective international registry to confirm that IAB is associated with a high risk of AF and stroke in the elderly population with heart disease [22]. After showing the magnitude of this association, the second step is to perform a randomized control trial to test the benefits of anticoagulation in patients with heart disease, sinus rhythm, and A-IAB [23], probably adding as inclusion criteria other factor related with AF and stroke as advanced age [24] and atrial ectopy [25]. Our hypothesis also opens the door to other drugs, for instance as the renin-angiotensin-aldosterone system inhibition might have a role in the reduction of the risk of developing new onset AF [26], these medications might improve prognosis of patients with advanced IAB.
Finally, we would like to clarify that our hypothesis is based on data of patients without rheumatic heart disease. However, patients with IAB and rheumatic disease probably have an even higher risk of stroke as the burden of atrial fibrosis is noteworthy in patients with AF and rheumatic heart disease [27].

Conclusions

The presence of IAB, which is easily identifiable on surface ECG, may be a marker of a chain of events that leads to AF and stroke. IAB is common in the elderly and may be considered as a surrogate marker of atrial fibrosis. Patients with heart disease and IAB might benefit from early anticoagulation even without documented AF. This hypothesis needs to be confirmed with larger studies.

Acknowledgements

Not applicable.

Funding

Not applicable.

Availability of data and materials

Not applicable.
Not applicable.
Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Literatur
1.
Zurück zum Zitat Kottkamp H. Human atrial fibrillation substrate: towards a specific fibrotic atrial cardiomyopathy. Eur Heart J. 2013;34:2731–8.CrossRefPubMed Kottkamp H. Human atrial fibrillation substrate: towards a specific fibrotic atrial cardiomyopathy. Eur Heart J. 2013;34:2731–8.CrossRefPubMed
2.
Zurück zum Zitat Goyal S, Spodick D. Electromechanical dysfunction of the left atrium associated with interatrial block. Am Heart J. 2001;142:823–7.CrossRefPubMed Goyal S, Spodick D. Electromechanical dysfunction of the left atrium associated with interatrial block. Am Heart J. 2001;142:823–7.CrossRefPubMed
3.
Zurück zum Zitat Glotzer TV, Daoud EG, Wyse DG, et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk. The TRENDS Study Circ Arrhythm Electrophysiol. 2009;2:474–80.CrossRefPubMed Glotzer TV, Daoud EG, Wyse DG, et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk. The TRENDS Study Circ Arrhythm Electrophysiol. 2009;2:474–80.CrossRefPubMed
4.
Zurück zum Zitat Bayés de Luna A, Platonov P, Cosio FG, et al. Interatrial blocks. A separate entity from left atrial enlargement: a consensus report. J Electrocardiol. 2012;45:445–51.CrossRefPubMed Bayés de Luna A, Platonov P, Cosio FG, et al. Interatrial blocks. A separate entity from left atrial enlargement: a consensus report. J Electrocardiol. 2012;45:445–51.CrossRefPubMed
5.
Zurück zum Zitat Martínez-Sellés M, Massó-van Roessel A, Álvarez-Garcia J, (The investigators of the cardiac and clinical characterization of centenarians (4C) registry), et al. Interatrial block and atrial arrhythmias in centenarians: prevalence, associations, and clinical implications. Heart Rhythm. 2016;13:645–51.CrossRefPubMed Martínez-Sellés M, Massó-van Roessel A, Álvarez-Garcia J, (The investigators of the cardiac and clinical characterization of centenarians (4C) registry), et al. Interatrial block and atrial arrhythmias in centenarians: prevalence, associations, and clinical implications. Heart Rhythm. 2016;13:645–51.CrossRefPubMed
6.
Zurück zum Zitat Platonov PG, Mitrofanova LB, Orshanskaya V, Ho SY. Structural abnormalities in atrial walls are associated with presence and persistency of atrial fibrillation but not with age. J Am Coll Cardiol. 2011;58:2225–32.CrossRefPubMed Platonov PG, Mitrofanova LB, Orshanskaya V, Ho SY. Structural abnormalities in atrial walls are associated with presence and persistency of atrial fibrillation but not with age. J Am Coll Cardiol. 2011;58:2225–32.CrossRefPubMed
7.
Zurück zum Zitat Cosio FG, Palacios J, Vidal JM. Electrophysiologic studies in atrial fibrillation. Slow conduction of premature impulses: a possible manifestation of the background for reentry. Am J Cardiol. 1983;51:122–30.CrossRefPubMed Cosio FG, Palacios J, Vidal JM. Electrophysiologic studies in atrial fibrillation. Slow conduction of premature impulses: a possible manifestation of the background for reentry. Am J Cardiol. 1983;51:122–30.CrossRefPubMed
8.
Zurück zum Zitat Bayés de Luna A, Cladellas M, Oter R, et al. Interatrial conduction block and retrograde activation of the left atrium and paroxysmal supraventricular tachyarrhythmia. Eur Heart J. 1988;9:1112–8.CrossRefPubMed Bayés de Luna A, Cladellas M, Oter R, et al. Interatrial conduction block and retrograde activation of the left atrium and paroxysmal supraventricular tachyarrhythmia. Eur Heart J. 1988;9:1112–8.CrossRefPubMed
10.
Zurück zum Zitat Gul EE, Pal R, Caldwell J, et al. Interatrial block and interatrial septal thickness in patients with paroxysmal atrial fibrillation undergoing catheter ablation: Long-term follow-up study. Ann Noninvasive Electrocardiol. 2017;22(4). doi:10.1111/anec.12428. Gul EE, Pal R, Caldwell J, et al. Interatrial block and interatrial septal thickness in patients with paroxysmal atrial fibrillation undergoing catheter ablation: Long-term follow-up study. Ann Noninvasive Electrocardiol. 2017;22(4). doi:10.​1111/​anec.​12428.
11.
Zurück zum Zitat Spodick DH, Ariyarajah V. Interatrial block: the pandemic remains poorly perceived. Pacing Clin Electrophysiol. 2009;32:667–72.CrossRefPubMed Spodick DH, Ariyarajah V. Interatrial block: the pandemic remains poorly perceived. Pacing Clin Electrophysiol. 2009;32:667–72.CrossRefPubMed
12.
Zurück zum Zitat O'Neal WT, Zhang ZM, Loehr LR, et al. Electrocardiographic advanced interatrial block and atrial fibrillation risk in the general population. Am J Cardiol. 2016;117:1755–9.CrossRefPubMedPubMedCentral O'Neal WT, Zhang ZM, Loehr LR, et al. Electrocardiographic advanced interatrial block and atrial fibrillation risk in the general population. Am J Cardiol. 2016;117:1755–9.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Ariyarajah V, Puri P, Apiyasawat S, Spodick DH. Interatrial block: a novel risk factor for embolic stroke? Ann Noninv Electrocardiol. 2007;12:15–20.CrossRef Ariyarajah V, Puri P, Apiyasawat S, Spodick DH. Interatrial block: a novel risk factor for embolic stroke? Ann Noninv Electrocardiol. 2007;12:15–20.CrossRef
15.
Zurück zum Zitat Wu JT, Wang SL, Chu YJ, et al. CHADS2 and CHA2DS2-VASc scores predict the risk of ischemic stroke outcome in patients with interatrial block without atrial fibrillation. J Atheroscler Thromb. 2017;24:176–84.CrossRefPubMedPubMedCentral Wu JT, Wang SL, Chu YJ, et al. CHADS2 and CHA2DS2-VASc scores predict the risk of ischemic stroke outcome in patients with interatrial block without atrial fibrillation. J Atheroscler Thromb. 2017;24:176–84.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Longobardo L, Todaro MC, Zito C, et al. Role of imaging in assessment of atrial fibrosis in patients with atrial fibrillation: state-of-the-art review. Eur Heart J Cardiovasc Imaging. 2014;15:1–5.CrossRefPubMed Longobardo L, Todaro MC, Zito C, et al. Role of imaging in assessment of atrial fibrosis in patients with atrial fibrillation: state-of-the-art review. Eur Heart J Cardiovasc Imaging. 2014;15:1–5.CrossRefPubMed
17.
Zurück zum Zitat Lacalzada-Almeida J, García-Niebla J, Bayés-de LA. Speckle-tracking echocardiography and advanced interatrial block. Rev Esp Cardiol. 2017;70:591.CrossRefPubMed Lacalzada-Almeida J, García-Niebla J, Bayés-de LA. Speckle-tracking echocardiography and advanced interatrial block. Rev Esp Cardiol. 2017;70:591.CrossRefPubMed
18.
Zurück zum Zitat Montserrat S, Gabrielli L, Bijnens B, et al. Left atrial deformation predicts success of first and second percutaneous atrial fibrillation ablation. Heart Rhythm. 2015;12:11–8.CrossRefPubMed Montserrat S, Gabrielli L, Bijnens B, et al. Left atrial deformation predicts success of first and second percutaneous atrial fibrillation ablation. Heart Rhythm. 2015;12:11–8.CrossRefPubMed
19.
Zurück zum Zitat Benito EM, De Luna AB, Baranchuk A, Mont L. Extensive atrial fibrosis assessed by late gadolinium enhancement cardiovascular magnetic resonance associated with advanced interatrial block electrocardiogram pattern. Europace. 2017;19:377.CrossRefPubMed Benito EM, De Luna AB, Baranchuk A, Mont L. Extensive atrial fibrosis assessed by late gadolinium enhancement cardiovascular magnetic resonance associated with advanced interatrial block electrocardiogram pattern. Europace. 2017;19:377.CrossRefPubMed
20.
Zurück zum Zitat Martínez-Sellés M, Fernández Lozano I, Baranchuk A, et al. Should we anticoagulate patients at high risk of atrial fibrillation? Rev Esp Cardiol. 2016;69:374–6.CrossRefPubMed Martínez-Sellés M, Fernández Lozano I, Baranchuk A, et al. Should we anticoagulate patients at high risk of atrial fibrillation? Rev Esp Cardiol. 2016;69:374–6.CrossRefPubMed
21.
Zurück zum Zitat Bayés de Luna A, Baranchuk A, Martínez-Sellés M, et al. Anticoagulation in patients at high risk of stroke without documented atrial fibrillation. Time for a paradigm shift? Ann Noninvasive Electrocardiol. 2017;22(1). doi:10.1111/anec.12417. Bayés de Luna A, Baranchuk A, Martínez-Sellés M, et al. Anticoagulation in patients at high risk of stroke without documented atrial fibrillation. Time for a paradigm shift? Ann Noninvasive Electrocardiol. 2017;22(1). doi:10.​1111/​anec.​12417.
22.
Zurück zum Zitat Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation. 2012;125:2298–307.CrossRefPubMed Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation. 2012;125:2298–307.CrossRefPubMed
23.
Zurück zum Zitat Martínez-Sellés M, Baranchuk A, Elosua R, de Luna AB. Rationale and design of the BAYES (interatrial block and yearly EventS) registry. Clin Cardiol. 2017;40:196–9.CrossRefPubMed Martínez-Sellés M, Baranchuk A, Elosua R, de Luna AB. Rationale and design of the BAYES (interatrial block and yearly EventS) registry. Clin Cardiol. 2017;40:196–9.CrossRefPubMed
25.
Zurück zum Zitat Kumarathurai P, Mouridsen MR, Mattsson N, Larsen BS, Nielsen OW, Gerds TA, Sajadieh A. Atrial ectopy and N-terminal pro-B-type natriuretic peptide as predictors of atrial fibrillation: a population-based cohort study. Europace. 2017 Mar 1;19:364–70.PubMed Kumarathurai P, Mouridsen MR, Mattsson N, Larsen BS, Nielsen OW, Gerds TA, Sajadieh A. Atrial ectopy and N-terminal pro-B-type natriuretic peptide as predictors of atrial fibrillation: a population-based cohort study. Europace. 2017 Mar 1;19:364–70.PubMed
26.
Zurück zum Zitat Khatib R, Joseph P, Briel M, Yusuf S, Healey J. Blockade of the renin-angiotensin-aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: a systematic review and meta analysis of randomized controlled trials. Int J Cardiol. 2013;165:17–24.CrossRefPubMed Khatib R, Joseph P, Briel M, Yusuf S, Healey J. Blockade of the renin-angiotensin-aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: a systematic review and meta analysis of randomized controlled trials. Int J Cardiol. 2013;165:17–24.CrossRefPubMed
27.
Zurück zum Zitat Zhang L, Zhang N, Tang X, Liu F, Luo S, Xiao H. Increased α-actinin-2 expression in the atrial myocardium of patients with atrial fibrillation related to rheumatic heart disease. Cardiology. 2016;135:151–9.CrossRefPubMed Zhang L, Zhang N, Tang X, Liu F, Luo S, Xiao H. Increased α-actinin-2 expression in the atrial myocardium of patients with atrial fibrillation related to rheumatic heart disease. Cardiology. 2016;135:151–9.CrossRefPubMed
Metadaten
Titel
Surface ECG interatrial block-guided treatment for stroke prevention: rationale for an attractive hypothesis
verfasst von
Antoni Bayés de Luna
Manuel Martínez-Sellés
Antoni Bayés-Genís
Roberto Elosua
Adrian Baranchuk
Publikationsdatum
01.12.2017
Verlag
BioMed Central
Erschienen in
BMC Cardiovascular Disorders / Ausgabe 1/2017
Elektronische ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-017-0650-y

Weitere Artikel der Ausgabe 1/2017

BMC Cardiovascular Disorders 1/2017 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.